Şunu aradınız:: haemangioma (İngilizce - Slovence)

haemangioma
hemangiom

haemangioma can be superficial or deep.
hemangiom je lahko površinski ali globok.

life- or function-threatening haemangioma,
hemangiom, ki ogroža življenje ali telesne funkcije,

this medicine is used to treat a disease called haemangioma.
zdravilo se uporablja za zdravljenje bolezni, imenovane hemangiom.

the committee concluded that hemangiol was an effective treatment for haemangioma.
odbor je zaključil, da je hemangiol učinkovito zdravilo za zdravljenje hemangioma.

hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:
zdravilo hemangiol je indicirano za zdravljenje hitro rastočega infantilnega hemangioma, ki zahteva sistematično zdravljenje:

a haemangioma is a collection of extra blood vessels that have formed a lump in or under the skin.
hemangiom je tvorba dodatnih krvnih žil, ki se oblikujejo v bulo v koži ali pod kožo.

hemangiol may increase potassium blood level (hyperkaliemia) in case of large ulcerated haemangioma.
zdravilo hemangiol lahko poveča raven kalija v krvi (hiperkaliemija) v primeru velikega ulceriranega hemangioma.

treatment should be started by a doctor who has experience in the diagnosis, treatment and management of infantile haemangioma.
zdravljenje mora uvesti zdravnik, ki ima izkušnje z diagnosticiranjem, zdravljenjem in oskrbo infantilnega hemangioma.

in rats, the incidence of benign haemangioma of the mesenteric lymph nodes was higher in some groups than in concurrent controls.
pri podganah je bila incidenca benignih hemangiomov mezenteričnih bezgavk v nekaterih skupinah večja kot pri sočasni kontrolni skupini.

it is sometimes called ‘strawberry mark’ because the surface of a haemangioma looks a bit like a strawberry.
včasih ga imenujemo »jagodno znamenje«, saj površina hemangioma spominja na jagodo.

for ethical reasons related to the use of placebo, the demonstration of the efficacy was not established in patients with high-risk haemangioma.
iz etičnih razlogov, povezanih z uporabo placeba, dokazov učinkovitosti niso ugotavljali pri bolnikih s hemangiomom z visoko stopnjo tveganja.

evidence of the efficacy of propranolol in patients with high- risk haemangioma is available both in literature and in a specific compassionate use program performed with hemangiol.
dokazi o učinkovitosti propranolola pri bolnikih s hemangiomom z visoko stopnjo tveganja so na voljo v literaturi in v specifičnem programu sočutne uporabe, izvedenim z zdravilom hemangiol.

patients with infantile haemangioma may be at increased risk if they have received or are concomitantly receiving treatment with corticosteroids because adrenal suppression may result in loss of the counterregulatory cortisol response and increase the risk of hypoglycaemia.
pri bolnikih z infantilnim hemangiomom je morda povečano tveganje, če so bili zdravljeni ali se sočasno zdravijo s kortikosteroidi, saj lahko supresija nadledvične žleze privede do izgube protiregulatornega odziva na kortizol in poveča tveganje hipoglikemije.

the educational pack must be available for distribution prior to the launch of the new indication (treatment of proliferating infantile haemangioma) in the member state.
izobraževalni paket mora biti na voljo za distribucijo pred uvedbo nove indikacije (zdravljenje hitro rastočega infantilnega hemangioma) v državi članici.

treatment success was defined as a complete or nearly complete resolution of the target haemangioma, which was evaluated by blinded centralized independent assessments made on photographs at week 24, in the absence of premature treatment discontinuation.
uspešnost zdravljenja je bila določena kot dokončno ali skoraj dokončno izginotje ciljnega hemangioma, ki je bil ocenjen s slepo centralizirano, neodvisno oceno na osnovi fotografij v 24. tednu, zdravljenje pa ni bilo predčasno prekinjeno.

it is used to treat children with proliferating infantile haemangioma, which are benign tumours (abnormal non-cancerous growths) of blood vessels.
uporablja se za zdravljenje otrok s hitro rastočimi infantilnimi hemangiomi, ki so benigni tumorji (nenormalne nerakave tvorbe) krvnih žil.

in clinical trials for proliferating infantile haemangioma, the most frequently reported adverse reactions in infant treated with hemangiol were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhoea, and vomiting.
pri kliničnih preizkušanjih hitro rastočega infantilnega hemangioma so bili neželeni učinki, o katerih so največkrat poročali pri dojenčkih, zdravljenih z zdravilom hemangiol, motnje spanja, poslabšanje okužb dihalnih poti, kot sta bronhitis in bronhiolitis, povezana s kašljem in z vročino, driska in bruhanje.

age (35-90 days / 91- 150 days), gender and haemangioma location (head / body) subgroups did not identify differences in response to propranolol.
pri podskupinah po starosti (od 35 do 90 dni/od 91 do 150 dni), spolu in lokaciji hemangioma (glava/telo) ni bilo odkritih razlik v odzivu na propranolol.